rg4733
Stage IIIC Colon Cancer
National Cancer Institute (NCI)Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 23/ 100
- Competitive Position
- 95/ 100
Competitive context
47 Active assets in the Stage IIIC Colon Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Merck Sharp & Dohme LLC | Phase 3 | BBB |
Eloxatin Sun Yat-sen University | Phase 3 | BBB |
Irinotecan Sun Yat-sen University | Phase 3 | BBB |
Irinotecan SWOG Cancer Research Network | Phase 3 | BBB |
Eloxatin Merck Sharp & Dohme LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
rg4733 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →